⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ocugen, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Ocugen, Inc.
↗Malvern, Pennsylvania, USA
Ocugen is a clinical-stage biotechnology company focused on developing and commercializing novel gene and cell therapies, biologics, and vaccines. The company is primarily recognized for its modifier gene therapy platform, which employs a gene-agnostic approach to treat various inherited retinal disorders, including retinitis pigmentosa, Stargardt disease, and geographic atrophy.
In addition to its ophthalmology pipeline, Ocugen maintains research programs in infectious diseases, including an inhaled mucosal vaccine platform, and orthopedic therapies through its subsidiary. The company is currently advancing multiple candidates toward late-stage clinical trials and regulatory filings.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$1M-$10M
Founded:2013
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:NASDAQ
Ticker:OCGN
Market Cap:$0.4B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (OCU400)
Modalities:Gene therapy, Biologics, Vaccines, Cell therapy
Active Trials:4
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:OrthoCellix
Key Partnerships:NIAID (Project NextGen for OCU500 vaccine)
COMPETITION
Position:Emerging
Competitors:Nanoscope Therapeutics, Editas Medicine, Intellia Therapeutics
LEADERSHIP
Key Executives:
Shankar Musunuri - Chairman, CEO and Co-Founder
Rita Johnson-Greene - CFO
Scientific Founders:Shankar Musunuri, Uday B. Kompella
LINKS
Website:ocugen.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ocugen, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.